A comparative study on the therapeutic effect of combined NBUVB and systemic Simvastatin with NBUVB alone in patients with vitiligo

A comparative study on the therapeutic effect of combined NBUVB (Narrow Band Ultraviolet B) and systemic Simvastatin with NBUVB alone in patients with vitiligo

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191013045092N2

Enrollment

Registered

2021-01-01

Start date

2015-10-16

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

The first group of simvastatin 20 mg made by Iranian company Poursina (first month 2 times a day in the second month 3 times a day in the third and fourth month 4 times a day) and the placebo group (m

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who have just started treatment and have not taken medication in the last 6 months

Exclusion criteria

Exclusion criteria: Patients with liver and kidney problems Pregnant or breastfeeding Patients taking simvastatin interfering drug Under 16 years old

Design outcomes

Primary

Measure	Time frame
Investigation of skin re-pigmentation rate. Timepoint: Months 1, 2, 3 and 4. Method of measurement: Repetition of experiments, photography and scoring.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ladan Dastgheib

Shiraz University of Medical Sciences

dastgh@sums.ac.ir+98 71 3231 9049

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026